45% have interest in voice-assisted health management

Interest in AI technologies like voice search, assistants and chatbot are increasing as more patients takes steps to management their care, according to the DRG Digital - Manhattan Research's Cybercitizen Health U.S. 2017 study.

The study includes responses from 6,001 U.S. adults on their digital healthcare interest. Findings included:

  • One in four smartphone users now use voice search to access information.
  • 51 percent of Americans are interested in using voice-activated health management technology.
  • 45 percent are interested in using voice assistants for health, stating that the technology would change how they manage their health.
  • 69 percent of Crohn’s disease patients and 61 percent of patients with depression are interested in voice assistants for health management.
  • 32 percent of adults would prefer using an automated chat bot to navigate websites.

"The healthcare industry is notoriously slow to catch up with new technologies, but AI-powered tech shows great potential to modernize and improve care. For patients, AI promises a whole new user experience, faster access to care, a new source of medical advice and health management support," said DRG Senior Digital Analyst Gintare Greenfeld. "On the flip side, physicians are going to have to start coordinating care with Dr. Siri or Dr. Alexa."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.